Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with Gemcitabine and Cisplatin in Advanced Renal Collecting Duct Carcinoma
NCT01762150Phase 2Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jun 2011
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in collecting duct carcinoma (CDC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression-Free Survival. Started Jun 2011; status: completed.
02
Drugs
sorafenib
03
Conditions
collecting duct carcinoma (CDC)
Beyond the preview
Go deeper on NCT01762150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01762150.